参考文献/References:
[1]Miyachi H. Structural biology-based exploration of subtype-selective agonists for peroxisome proliferator-activated receptors[J]. Int J Mol Sci,2021,22(17):9223.
[2]Huttunen JK,Heinsalmi P,Manninen V,et al.Helsinki Heart Study.New perspectives in the prevention of coronary heart disease[J]. Drugs,1988,36(suppl 3):32-36.
[3]Goldenberg I,Benderly M,Goldbourt U.Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia:an extended follow-up of the BIP trial[J]. J Am Coll Cardiol,2008,51(4):459-465.
[4]Ginsberg HN,Elam MB,Lovato LC,et al.Effects of combination lipid therapy in type 2 diabetes mellitus[J]. New Engl J Med,2010,362(17):1563-1574.
[5]Wayman NS,Hattori Y,McDonald MC,et al.Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size[J]. FASEB J,2002,16(9):1027-1040.
[6]Yue TL,Bao W,Jucker BM,et al. Activation of peroxisome proliferator–activated receptor-α protects the heart from ischemia/reperfusion injury[J]. Circulation, 2003 ,108(19):2393-2399.
[7]Sambandam N,Morabito D,Wagg C,et al.Chronic activation of PPARα is detrimental to cardiac recovery after ischemia[J]. Am J Physiol Heart Circ. Physiol,2006,290(1):H87–H95.
[8]Liu JR,Cai GY,Ning YC,et al. Caloric restriction alleviates aging-related fibrosis of kidney through downregulation of miR-21 in extracellular vesicles[J]. Aging (Albany NY),2020,12(18):18052-18072.
[9]Keech AC Simes RJ,Barter PJ et al.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial[J]. Lancet,2005,366(9500):1849-1861.
[10]Xu Y,Lu L,Greyson C,et al.The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs[J]. Am J Physiol Heart Circ Physiol,2005,290(5):H1798–H1807.
[11]Shao Y,Chen J,Dong LJ,et al. A protective effect of PPARα in endothelial progenitor cells through regulating metabolism[J]. Diabetes,2019,68(11):2131-2142.
[12]Ibarra-Lara L,Sánchez-Aguilar M,Soria-Castro E,et al.Clofibrate treatment decreases inflammation and reverses myocardial infarction-induced remodelation in a rodent experimental model[J]. Molecules,2019,24(2):270.
[13]Papatheodorou I,Galatou E,Panagiotidis GD,et al. Cardioprotective effects of PPARβ/δ activation against ischemia/reperfusion injury in rat heart are associated with ALDH2 upregulation,amelioration of oxidative stress and preservation of mitochondrial energy production[J]. Int J Mol Sci,2021,22(12):6399.
[14]Kappert,K,B?hm,M,Schmieder R,et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk:analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial (ONTARGET)[J]. Circulation,2012,126(8):934-941.
[15]Wagner N,Wagner KD. PPARs and angiogenesis—implications in pathology[J]. Int J Mol Sci,2020,21(16):5723.
[16]Jucker BM,Doe CP,Schnackenberg CG,et al.PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure[J]. J Cardiovasc Pharmacol,2007,50(1):25-34.
[17]Wagner N,Wagner KD. PPAR beta/delta and the hallmarks of cancer[J]. Cells,2020,9(5):1133.
[18]Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. New Engl J Med,2007,356(24):2457-2471.
[19]Jang SY,Jang J,Yang DH,et al. Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus[J]. Cardiovasc Diabetol,2021,20(1):180.
[20]Graham DJ,Ouellet-Hellstrom R,MaCurdy TE,et al.Risk of acute myocardial infarction,stroke,heart failure,and death in elderly medicare patients treated with rosiglitazone or pioglitazone[J].JAMA,2010,304(4):411-418.
[21]Kaul S,Bolger AF,Herrington D,et al.Thiazolidinedione drugs and cardiovascular risks:a science advisory from the American Heart Association and American College of Cardiology Foundation [J].Circulation,2010,121(16):1868-1877.
[22]Doney AS,Fischer B,Leese G,et al.Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus:a Go-DARTS study [J].Arter.Thromb.Vasc.Biol.2004,24(12):2403-2407.
[23]Zou G,Zhou Z,Xi X,et al. Pioglitazone ameliorates renal ischemia-reperfusion injury via inhibition of NF-κB activation and inflammation in rats[J]. Front Physiol,2021,12:707344.
[24]Chandra M,Miriyala S,Panchatcharam M. PPARγ and its role in cardiovascular diseases[J]. PPAR Res,2017,2017:6404638.
[25]Liu HR,Tao L,Gao E,et al. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation—a novel mechanism for the cardioprotective effects of PPAR agonists [J]. Cardiovasc Res,2008,81(2):344-352.
[26]Shehata AHF,Ahmed AF,Abdelrehim AB,et al. The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion[J]. Life Sci,2020,252:117679.
[27]Zhang XJ,Xiong ZB,Tang AL,et al.Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway[J].Clin Exp Pharmacol Physiol,2010,37(2):156-161.
[28]Zhou L,Wang ZZ,Xiao ZC,et al. Effects of PPAR-γ in the myocardium on the development of ventricular septation[J]. Curr Med Sci,2020,40(2):313-319.
[29]Zhao X,Wang F,Zhou R,et al. PPARα/γ antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats[J]. Inflammopharmacology,2018,26(2):425-433.
[30]Cheng HS,Tan WR,Low ZS,et al. Exploration and development of PPAR modulators in health and disease:an update of clinical evidence[J]. Int J Mol Sci,2019,20(20):5055.
相似文献/References:
[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(12):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]孙洋.基质金属蛋白酶与心肌梗死后心脏重构[J].心血管病学进展,2019,(8):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
SUN Yang.Matrix Metalloproteinases in Cardiac Remodeling after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(12):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(12):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(12):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[5]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(12):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[6]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(12):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(12):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[8]黄柳,张瑞宁,田小超,等.内皮祖细胞与冠心病患者CD14CD16+单核细胞共培养后移植心肌梗死大鼠对血管密度及心肌梗死面积的影响[J].心血管病学进展,2020,(2):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
HUANG Liu,ZHANG Ruining,TIAN Xiaochao,et al.Effects of Co-cultured Endothelial Progenitor Cells and CD14++CD16+ Monocytes from Coronary Heart Disease Patients on Vascular Density and Myocardial Infarction Size in Transplanting Myocardial Infarction Rats[J].Advances in Cardiovascular Diseases,2020,(12):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
[9]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(12):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[10]谢建华,赵鸿泽,刘剑雄.MicroRNA在心肌梗死后左室重塑和心力衰竭发展中的研究现状[J].心血管病学进展,2020,(3):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
XIE Jianhua,ZHAO Hongze,LIU Jianxiong.MicroRNA in Development of Left Ventricular Remodeling and Heart Failure after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(12):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]